Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13452484 | 0.85 | KDM1A (0.46) | MAOAKDM1AMAOBCA12CA1 | |
| SCHEMBL5562690 | 0.85 | MAOA (0.53) | MAOAKDM1AMAOBCA12CA1 | |
| SCHEMBL1639545 | 0.85 | MAOA (0.53) | MAOAKDM1AMAOBCA12CA1 | |
| Bromide SCHEMBL11252079 | 0.83 | MAOA (0.51) | MAOAKDM1AMAOBGID4ALDH1A1 | |
| SCHEMBL13801056 | 0.83 | KDM1A (0.44) | MAOAKDM1AMAOBCA12CA1 | |
| Hydrochloric Acid SCHEMBL28782088 | 0.83 | MAOA (0.51) | MAOAKDM1AMAOBGID4ALDH1A1 | |
| SCHEMBL6868706 | 0.82 | MAOA (0.50) | MAOAKDM1AMAOBGID4ALDH1A1 | |
| SCHEMBL3163003 | 0.80 | KDM1A (0.42) | MAOAKDM1AMAOBALDH1A1TDP1 | |
| SCHEMBL164122 | 0.78 | MEN1 (0.59) | MAOAKDM1AMAOBGID4 | |
| SCHEMBL31494195 | 0.78 | MEN1 (0.59) | MAOAKDM1AMAOBGID4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988349-B2 | Direct stereospecific synthesis of unprotected aziridines from olefins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-05 | — | — | US | disclosed |
| US-9006231-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140171416-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2014-06-19 | — | — | US | disclosed |
| US-8466142-B2 | Cephalotaxus esters, methods of synthesis, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-06-18 | — | — | US | disclosed |
| EP-2394989-A1 | Method for producing a N-substituted aziridine | BASF SE (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20110071097-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2275408-A1 | Method for synthesizing a n-substituted aziridine | BASF SE (DE) | 2011-01-19 | — | — | EP | disclosed |
| US-20100191000-A1 | METHOD FOR SYNTHESIZING AN N-UNSUBSTITUTED OR N-SUBSTITUTED AZIRIDINE | BASF SE (DE) | 2010-07-29 | — | — | US | disclosed |
| CN-101679234-A | Method for synthesizing N-unsubstituted or N-substituted aziridine | BASF SE | 2010-03-24 | — | — | CN | disclosed |
| EP-2160379-A1 | METHOD FOR SYNTHESIZING AN N-UNSUBSTITUTED OR N-SUBSTITUTED AZIRIDINE | BASF SE (DE) | 2010-03-10 | — | — | EP | disclosed |
| WO-2009148654-A2 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2008155355-A1 | METHOD FOR SYNTHESIZING AN N-UNSUBSTITUTED OR N-SUBSTITUTED AZIRIDINE | BASF SE (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100191000-A1 | METHOD FOR SYNTHESIZING AN N-UNSUBSTITUTED OR N-SUBSTITUTED AZIRIDINE | CBR1, CBR3, AOC2 | MAOA 166/4885KDM1A 2786/4885MAOB 46/4885 |
| US-20110071097-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | COASY, CXCR4, CETP | MAOA 3151/4885KDM1A 852/4885MAOB 2562/4885 |
| US-20140171416-A1 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF | COASY, CXCR4, CETP | MAOA 3151/4885KDM1A 852/4885MAOB 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.